Head-to-head comparison
AquaVita NextGen vs SkinnyRx
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
AquaVita NextGen (AquaVita Wellness & Medspa) offers compounded semaglutide and tirzepatide (ODT tablets).
$375/mo (first month only) sema · $320/mo (3-month prepay) tirz · Verified July 2026
Marked down on: Only 5 states (AZ, CA, FL, TX, NV)
Desk Score
Both molecules by needle or by tablet, with the whole term ladder printed on the product page before any intake — and a headline rate that is the twelve-month rung, charged as one $2,388 payment on day one.
$349/mo sema · $399/mo tirz · Verified August 2026
Marked down on: FDA issued Lean Rx, Inc. dba SkinnyRx a warning letter in February 2026; the letter is public in FDA's warning-letter database
FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.
SkinnyRx takes this head-to-head with the higher Desk Score, 78/100 (C+) against 65/100 (C) for AquaVita NextGen. AquaVita NextGen still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
AquaVita NextGen
65/100
C
SkinnyRx
78/100
C+
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | AquaVita NextGen | SkinnyRx |
|---|---|---|
| Semaglutide | $375/mofirst month only$375/mo (first-month rate, compounded) | $349/mo$349/mo month-to-month (compounded; the advertised rate is a 12-month prepay) |
| Tirzepatide | $320/mo3-month prepay$320/mo (starting dose, 3-month plan, compounded) | $399/mo$399/mo month-to-month (compounded; the advertised rate is a 12-month prepay) |
| Coverage | 5 states | 47 states + DC (not Alabama, Louisiana or Mississippi) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Yes | Yes |
| Best for | Patients in AZ/CA/FL/TX/NV seeking medspa-backed GLP-1 with a named medical director. | People who want a tablet route on either molecule and can pay a year up front; anyone shopping month to month should compare $349 and $399, not the advertised $199 and $299. |
| Desk Score | 65/100C | 78/100C+ |
The verdict
Desk pick — SkinnyRxSkinnyRx takes this head-to-head with the higher Desk Score, 78/100 (C+) against 65/100 (C) for AquaVita NextGen. AquaVita NextGen still holds its ground where its strengths line up with yours.
Choose AquaVita NextGen if…
Patients in AZ/CA/FL/TX/NV seeking medspa-backed GLP-1 with a named medical director.
$375/mo (first month only) sema · $320/mo (3-month prepay) tirz · 5 states
Choose SkinnyRx if…
People who want a tablet route on either molecule and can pay a year up front; anyone shopping month to month should compare $349 and $399, not the advertised $199 and $299.
$349/mo sema · $399/mo tirz · 47 states + DC (not Alabama, Louisiana or Mississippi)
FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: AquaVita NextGen · SkinnyRx.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- AquaVita NextGen vs CoreAge Rx
- CoreAge Rx vs SkinnyRx
- Apex MD vs AquaVita NextGen
- Apex MD vs SkinnyRx
- AquaVita NextGen vs Kova
- NovoCare Pharmacy vs SkinnyRx
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.